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dUniversité de Bordeaux, Nutrition et Neurobiologie Intégrée, UMR, Bordeaux, France
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Abstract.
Background: Alzheimer’s disease (AD) is a multifactorial disease, implying that multi-target treatments may be necessary
to effectively cure AD. Tetrahydrobiopterin (BH4) is an enzymatic cofactor required for the synthesis of monoamines and
nitric oxide that also exerts antioxidant and anti-inflammatory effects. Despite its crucial role in the CNS, the potential of
BH4 as a treatment in AD has never been scrutinized.
Objective: Here, we investigated whether BH4 peripheral administration improves cognitive symptoms and AD neuropatho-
logy in the triple-transgenic mouse model of AD (3xTg-AD), a model of age-related tau and amyloid- (A) neuropathologies
associated with behavior impairment.
Methods: Non-transgenic (NonTg) and 3xTg-AD mice were subjected to a control diet (5% fat – CD) or to a high-fat diet
(35% fat - HFD) from 6 to 13 months to exacerbate metabolic disorders. Then, mice received either BH4 (15 mg/kg/day, i.p.)
or vehicle for ten consecutive days.
Results: This sub-chronic administration of BH4 rescued memory impairment in 13-month-old 3xTg-AD mice, as determined
using the novel object recognition test. Moreover, the HFD-induced glucose intolerance was completely reversed by the BH4
treatment in 3xTg-AD mice. However, the HFD or BH4 treatment had no significant impact on A and tau neuropathologies.
Conclusion: Overall, our data suggest a potential benefit from BH4 administration against AD cognitive and metabolic
deficits accentuated by HFD consumption in 3xTg-AD mice, without altering classical neuropathology. Therefore, BH4
should be considered as a candidate for drug repurposing, at least in subtypes of cognitively impaired patients experiencing
metabolic disorders.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common
form of dementia [1]. So far, there is no treatment
proven efficient to prevent or stop the progression of
the disease. AD is characterized by a cognitive de-
cline, hyperphosphorylated tau aggregated into neur-
ofibrillary tangles and the accumulation of amyloid-
(A) into senile plaques [2]. Beside these canonical
hallmarks, AD also involves defective monoamine
neurotransmission [3, 4], neuroinflammation [5, 6],
vascular impairment [7], and oxidative damage [8].
While the exact causes for the development of spo-
radic AD remain unknown, numerous risk factors
have been identified such as age, apolipoprotein 4
(ApoE4) carriage, and cardiovascular pathologies.
More recently, obesity, diabetes, and metabolic syn-
drome have been added to the list of key risk factors of
AD [9, 10]. Indeed, these metabolic disturbances lead
to increased neuroinflammation and oxidative stress
but also alterations in neuronal activity and vascular
function associated with cognitive decline [11, 12].
Neuroinflammation and oxidative stress have long
been associated with AD neuropathology and emerg-
ing evidence suggest these alterations may play a key
role in the relationship between metabolic disorders
and AD [9]. Impairments in dopaminergic and sero-
toninergic pathways have also been implicated in the
constellation of cognitive or behavioral symptoms
seen in AD [3, 13–15]. In light of these observations,
the paradigm “one-drug-one-target” has been chal-
lenged and a more holistic approach has emerged, to
include targets outside of the CNS [16, 17]. Overall,
there is growing recognition that AD is a multifacto-
rial disease and that multi-target treatments allowing
the modulation of the multiple defects observed in
AD are needed [9, 18].
Tetrahydrobiopterin (BH4) is mostly known as the
main enzymatic cofactor required for the synthesis of
serotonin (5-HT), dopamine (DA), and nitric oxide
(NO) [19]. BH4 is synthesized by all cells from GTP
and is readily oxidized to dihydrobiopterin (BH2),
its inactive form [20]. Moreover, a fraction of BH2
can be re-oxidized in BH4 by the dihydrobiopterin
reductase. BH4 plays crucial roles in the CNS, as a
cellular antioxidant, regulating the redox function of
endothelial NO synthase (eNOS) [21, 22], scaveng-
ing oxygen radicals [23] and monoamines production
[24–27].
Interestingly, BH4 and its metabolites (BH2 and
other oxidized biopterin) have been shown to be
decreased in serum [28], cerebrospinal fluid [29], and
temporal lobe from elderly or AD patients [27, 30].
Furthermore, neopterin, a BH4 derivative produced in
inflammatory conditions, is increased in the plasma
of AD patients and correlates with cognitive decline
[31–33]. In vivo evidence obtained in Tg2576 mice, a
model that overexpresses mutated human amyloid-
protein precursor (APP), suggests that A peptides
induce an increase in production of superoxide anion
leading to BH4 oxidation in BH2 [34]. Conversely, it
has been shown that a genetic increase in BH4 syn-
thesis in endothelial cells of ApoE-knockout mice
reduces vascular oxidative stress and restores NO
signaling [35]. Interestingly, BH4 administration in
mice and in humans was reported to improve glu-
cose intolerance and insulin resistance, two markers
of peripheral metabolic disorders, which are also risk
factors for AD [36–38]. More recent evidence shows
that BH4 crosses the blood-brain barrier, influenc-
ing dopamine release and improving performance in
motivational tasks [39]. Although these data suggest
that BH4 may act on several key aspects of AD patho-
genesis, the potential of BH4 to improve symptoms
and pathology has never been studied.
The triple-transgenic mouse model of AD (3xTg-
AD) develops memory deficits and the two main neu-
ropathological markers of the disease, namely amy-
loid plaques and neurofibrillary tangles, while aging
[40–42]. Chronic consumption of high-fat diet (HFD)
further increases neuropathologies and accelerates
cognitive impairment [43–47] in these mice and other
AD mouse models [48–54]. Several mechanisms
have been proposed for the effect of HFD on AD pat-
hology including changes in production/clearance
ratio of A [43, 46, 48, 55, 56], insulin-signaling dys-
regulations [54, 55, 57], and increased oxidative
stress [44] and inflammation [58]. Finally, BH4
is already administered in patients suffering from
genetic deficiency and its favorable safety profile has
been shown in clinical trials [59]. Thus, given its abi-
lity to regulate metabolism, oxidative stress, and in-
flammation, BH4 appears to be promising to treat the
HFD-induced increase in AD-like neuropathologies.
We hypothesized that BH4 administration could
ameliorate memory impairment in 3xTg-AD mice
owing to its action on different AD-relevant path-
ways. In order to exacerbate metabolic, inflammatory,
and oxidative disturbances in 3xTg-AD mice, ani-
mals were fed either a HFD or a control diet from the
age of 6 until 13 months. Then, mice were injected
daily with either BH4 (15 mg/kg) or a control solution
for ten consecutive days. The aim was to explore the
effect of BH4 treatment on cognitive impairment,
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cerebral neuropathologies, and HFD-induced met-
abolic defects in the 3xTg-AD mouse model.
METHODS
Animals
All experiments were performed in accordance
with the Canadian Council on Animal Care (CCAC)
and received prior authorization from the Univer-
sité Laval animal protection committee (CPAUL).
Triple-transgenic 3xTg-AD mice (APPswe, PSIMI46V,
tauP301L) (from Dr. LaFerla) [41] were maintained
in our animal facilities and backcrossed every seven
to ten generations to C57BL6/129SvJ mice. In this
model, A and tau pathologies become readily quan-
tifiable at ∼12 months of age, co-occurring with
cognitive deficits and glucose-related metabolic dis-
turbances [42, 43, 55, 60–63]. Serum cytokines were
previously studied in the 3xTg-AD model between 9
and 13 months of age [64].
Thus, the non-transgenic mice (NonTg), used as a
control group, were on the same background as tra-
nsgenic mice. Mice were housed one to five per cage
with a 12:12 h light-dark cycle (light phase from 7
a.m. to 7 p.m). Animals had ad libitum access to
water and diet. At the end of the experiment, mice
were killed by intracardiac perfusion with phosph-
ate saline buffer containing a cocktail of pro-
tease inhibitors (SIGMAFAST™ Protease Inhibitor
Tablets, Sigma-Aldrich, St Louis, MO, USA) and
phosphatase inhibitors (1 mM sodium pyrophosphate
and 50 mM sodium fluoride) under deep anesthe-
sia with ketamine/xylazine i.p. (100 mg/kg ketamine,
10 mg/kg xylazine). Brain was rapidly dissected on
ice, frozen and kept at –80◦C until processing. All
groups were composed of males and females in equal
proportion. All mice were randomly assigned to diet
and BH4 treatment groups.
Diets and treatment
Mice received either a control diet (CD – 12 % kCal
from fat) or a high-fat diet (HFD – 60 % kCal from fat)
for 7 months, from the age of 6 months until the end of
the experiment [43, 55]. The diet was manufactured
by Research Diets Inc. (New Brunswick, NJ) and
is described in detail in Supplementary Table 1. We
used purified diet formulations standardized to ensure
consistency and eliminate batch-to-batch variations,
containing measured concentrations of macronutri-
ents, vitamins, and minerals.
At the age of 13 months, mice were injected daily
with either a BH4 solution (15 mg/kg, i.p.) or a con-
trol solution (0.1 M HCl diluted in saline, i.p.) for
10 consecutive days prior sacrifice. This treatment
duration was selected from previous studies show-
ing that IV or oral administration of BH4 for 7–10
days was sufficient to alter neurotransmitters such
as DA, 5-HT and/or their metabolites [65–67]. Previ-
ous work shows that intraperitoneal administration of
BH4 (50 mg/kg, ip) leads to increased BH4 concen-
trations in the brain as well as increased dopamine
release and enhanced motivation in response to
amphetamine [39]. Using in-situ brain perfusion, the
brain uptake clearance (Clup) of BH4 was estimated
at 0.08 l g–1.s–1, consistent with a modest rate of
transport across the blood-brain barrier [39]. The dose
of 15 mg/kg is in the range of doses used in previous
clinical trials and animal studies [34, 68]. The BH4
stock solution (100 mg/mL) was prepared by dis-
solving 1 g of (6R)-5,6,7,8-Tetrahydro-L-biopterin
dihydrochloride (Schricks laboratories) in 10 mL of
0.1 M HCl and stored at –80◦C until use. Mice were
injected 2 h before the end of the light phase (5
p.m.) and after metabolic and behavior experiments
to avoid potential stress induction by the i.p. injection.
Behavioral testing
All behavioral and metabolic tests were performed
from day 5 to day 10 of BH4 treatment, with a recov-
ery time of at least 24 h between tests. All behavioral
tests were conducted blindly, during the first 4 h of the
light phase. To minimize stress, mice were acclimated
to the testing room for 12 h before the test.
Spontaneous locomotion
Spontaneous locomotion was recorded at day 6 of
BH4 treatment using an open-field apparatus con-
sisting of clear boxes (40 × 40 × 40 cm) [42, 69].
Horizontal locomotor activity was recorded by the
interruption of crossing photosensitive beams (San
Diego Instrument). Mice were placed in the center of
the open-field and their activity (total distance trav-
elled in cm) was recorded for 1 h. The speed of mice
was also calculated and expressed as cm/min.
Recognition memory
Recognition memory was assessed using the novel
object recognition test (NOR) at days 7 and 8 of BH4
treatment, as previously described [55, 69]. The NOR
test is based on the spontaneous tendency of rodents to
explore a new object for longer than a familiar object.
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This task was selected based on the short period of
time available for assessing both cognition and glu-
cose tolerance in the same animals. In addition, com-
pared with other frequently used behavior tests, it is
less sensitive to sensorimotor dysfunction, anxiety or
thermoregulatory deficits, which are commonly rep-
orted in the 3xTg-AD mouse [55, 61, 69–73].
During the acquisition phase, mice were placed in a
clear box (29.2 x 19 x 12.7 cm) and allowed to explore
two similar objects for 5 min. Mice were returned to
their housing cage for 1 h and then presented with a
familiar (F) and a novel (N) object (testing phase) in
the same box for 5 min. The novel object was ran-
domly placed at the exact location of one of the two
familiar objects. The recognition index was defined
as the time exploring the novel object divided by the
total exploration time during the testing phase and
expressed as a percentage. The NOR test assumes
that a mouse not recognizing the object have a ran-
dom chance of exploring each object (50%) [73]. A
mouse which identifies one of the objects as new will
spend more time exploring it. Therefore, its recog-
nition index will be higher than 50%. Thus, a lack
of discrimination between the novel and the famil-
iar object, i.e., a recognition index of 50 % or below,
was interpreted as impaired object recognition. Mice
showing poor exploration activity (i.e., less than 7 s of
exploration per object during the acquisition phase
and less than 10 s of total exploration time during
the testing phase) were excluded from the analysis of
the experiment.
Glucose tolerance test
Glucose tolerance tests were performed at the days
9 and 10 of BH4 treatment, mice were individually
housed in the testing room and fasted for 6 h before
glucose tolerance test with free access to water. Mice
received an injection of glucose (1 g/kg, i.p.) and gly-
cemia was measured at 0, 15, 30, 45, 60, 90, and
120 min after glucose injection, in a drop of blood
from the saphenous vein using a glucometer (One-
Touch UltraMini, LifeScan, Milpitas, CA).
Protein extraction and western immunoblotting
The day following the last BH4 administration,
parieto-temporal cortex and hippocampi were dis-
sected, weighed and processed by successive cen-
trifugation steps as previously described [55, 63],
resulting in a soluble fraction (intra- and extracellu-
lar Tris buffer (TBS)-soluble proteins), a deter-
gent-soluble fraction (membrane proteins) and a
detergent-insoluble fraction (aggregated proteins ex-
tracted with formic acid). Briefly, tissues were hom-
ogenized in TBS (0.05 M Tris Base, 0.138 M NaCl,
2.7 mM KCl with 1 mM EDTA) containing a protease
inhibitor cocktail (104 mM AEBSF, 80 M aprotinin,
5 mM bestatin, 1.5 mM E-64, 2 mM leupeptin and
1.5 mM pepstatin-A) and a phosphatase inhibitors
cocktail (100 mM Sodium fluoride, 100 mM sodium
orthovanadate, 400 mM sodium tartrate, 115 mM
sodium molybdate, 200 mM imidazole, 2.5 mM (-)-
p-bromotetramisole oxalate, 500 M cantharidin and
500 nM Microcystin LR, Microcystis aeruginosa)
obtained from by Bimake (Houston, TX). Samples
were sonicated (3×45 s) in a Sonic Dismembrator
apparatus (Thermo Fisher Scientific, Waltham, MA)
After a 20 min centrifugation at 100,000 g and collec-
tion of supernatant, the TBS-insoluble pellets were
sonicated in lysis buffer (150 mM NaCl, 10 mM
NaH2PO4, 1 mM EDTA, 1% Triton X-100, 0.5%
SDS and 0.5% deoxycholate) containing the same
protease and phosphatase inhibitors. After centrifu-
gation, the remaining fraction containing insoluble
proteins was resuspended in 99 % formic acid and
divided in two parts, and dried to eliminate acid re-
sidue. One part was solubilized in 1X Laemmli’s
buffer for western blotting and the other in guani-
dine hydrochloride (5 M in 0.05 M Tris-HCl) for
subsequent ELISAs.
Protein concentrations were determined using bic-
inchoninic acid assay (Thermo-pierce). Twenty L
of each sample were added in Laemmli’s loading
buffer to obtain a final concentration of 1.5 g/L
and heated to 70◦C for 5 min. A total of 15–22.5 g
of proteins per sample were separated by SDS-PAGE
and electroblotted onto PVDF membranes (Immo-
bilon, Millipore). Membranes were blocked in 0.5%
BSA and 5% dry milk in PBS-0.1% tween-20 and
then incubated with primary (listed in Supplemen-
tary Table 2) and secondary (HRP goat anti-rabbit
or goat anti-mouse, 1/50000, Jackson ImmunoRe-
search) antibodies. Band intensities (optical density,
OD) were revealed with Luminata Forte (Millipore)
and detected using myECL imager (Thermo Fisher
Scientific). Quantifications were performed blindly
on ImageLab software (Millipore), using a back-
ground subtraction when necessary and results were
expressed as relative OD.
Aβ40 and Aβ42 quantification
Human A40 and A42 contents were assessed in
TBS-soluble and detergent-insoluble fractions of
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protein extracts from parietotemporal cortices of
3xTg-AD mice using High Sensitive human -
Amyloid ELISA kits for A40 quantification (cat.
no.292-62301, FUJIFILM Wako Pure Chemical Cor-
poration) and for A42 quantification (cat.no.296-
6440, FUJIFILM Wako Pure Chemical Corporation)
according to the manufacturer’s instructions [74].
Briefly, plates were coated with anti-human-A[1–
16] MoAb [Clone No. BAN50] which recognizes
the N-terminal terminus of human A. Then, HRP-
conjugated Fab’ antibody BA27 (A40) or BC05
(A42) were used to specifically detects the C-ter-
minal of each A fragment. The cross reactivity of
murine A40 and A42 are <0.1 and 0.5% for the
A40 and the A42 ELISA kit, respectively.
High-performance liquid chromatography
Striatal monoamines and their main metabolites
were quantified as previously described [75]. Briefly,
striata were dissected on ice at the end of the 10
days of BH4-treatment, weighed and homogenized
in perchloric acid (0.1 N), centrifuged (13 000 rpm,
50 min, 4◦C) and supernatants were collected and
injected on an HPLC apparatus. The mobile phase
(8% methanol, 0.4 mM EDTA, 2 mM NaCl, 0.9 mM
octanic sulfonic acid, 55 mM NaH2PO4, pH 2.9) was
constantly delivered at 1.2 mL/min. Concentrations
were calculated using daily injected standards and
normalized to striatum weight.
Quantitative real-time PCR (qRT-PCR)
RNA from parietotemporal cortices was extracted
using RNeasy lipid tissue mini kit (Qiagen). Two
micrograms of RNA were reverse transcribed in
cDNA (High capacity cDNA reverse transcription
kit, Life technologies). Gene expression was mea-
sured using 80 nanograms of the resulting cDNA
in duplicates and appropriate FAM-labeled Taq-
man primers (Taqman gene expression assays, IL1
(Mm00434228 m1), IL6 (Mm00446190 m1), TNF-
 (Mm00443258 m1), GAPDH (Mm99999915 g1),
Life technologies). Data were analyzed using the
comparative threshold cycle method using GAPDH
as a housekeeping gene. Results are expressed as rel-
ative fold change with untreated NonTg CD mice as
the control group.
Nitrites/Nitrates brain levels
Nitrites and nitrates were measured as an indi-
cation of NO levels in the soluble fraction of
parietotemporal cortices. Forty L of each sample
were assayed on a nitrate/nitrite colorimetric assay kit
(Cayman) according to the manufacturers’ instruc-
tions. Results are expressed as the sum of nitrites and
nitrates levels, in moles/mg of wet tissue.
Statistical analysis
The main effects and interaction of the independent
variables (Sex, Diet, BH4-Treatment, and Genotype)
were evaluated using multifactorial ANOVA. Unless
a statistical effect of gender, males and females were
grouped and a 3-way ANOVA was performed, with
Time as a within-subjects repeated factor to compare
recurrent measurements in the same animals. When
variances were comparable between groups (Barlett’s
test), one-way ANOVAs were performed, followed
by Tukey’s tests. When variances were not compa-
rable, Kruskal Wallis tests followed by Wilcoxon
comparisons were used. All post-hoc comparisons
were made using the Tukey test. For the test of recog-
nition memory, a sample t-test was used to compare
means to the theoretical value of 50% (i.e., random/no
recognition); exploration times of the familiar and
novel objects were compared using the Wilcoxon
matched-pairs rank test.
Data are presented as mean ± SEM. All statistical
analyses were performed using GraphPad Prism 7
softwares. Statistical significance was set at p < 0.05.
RESULTS
The experimental design included male and female
NonTg and 3xTg-AD mice, exposed to either a con-
trol or a HFD from the age of 6 months. After 7
months of diet, the mice received an injection of
BH4 treatment for 10 days at 15 mg/kg/day. During
the treatment period, behavioral and metabolic tests
were performed. After the last day of treatment, the
mice were sacrificed, and the brain tissue was re-
moved for analysis (Fig. 1).
Mice were weighed at time of sacrifice, i.e., after
7 months of CD or HFD and 10 days after saline or
BH4 treatment. The multifactorial ANOVA revealed
a significant diet effect (p < 0.001), with a mean
body weight of 36.6 g in CD versus 42.8 g in HFD
mice (+17%), a genotype effect (p < 0.01), with a
reduced body weight in 3xTg-AD mice versus NonTg
(–10%). As expected, males had a significantly higher
body weight than females (p < 0.001) (+34%). How-
ever, the administration of BH4 had no effect on the
body weight of mice (Table 1).
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Fig. 1. Experimental design. Non-transgenic mice (NonTg) and triple-transgenic mice (3xTg-AD) mice were fed from the age of 6 months
a control (CD) or a high-fat diet (HFD) for 7 months. BH4 treatment (10 days, 15 mg/kg/day) was administered intra-peritoneally to mice at
the age of 13 months. Behavioral (Open Field, Object Recognition) and metabolic (Glucose Tolerance Test) tests were performed between
the 6th and 10th days of BH4 administration. On the day following the last injection, mice were sacrificed, and brain tissues were collected.
All group (n = 11–17) were composed of males and females in equal proportion.
BH4 administration improves recognition
memory in 3xTg-AD mice without affecting
spontaneous locomotion
We first evaluated object recognition memory after
6 days of BH4 administration in 3xTg-AD and NonTg
mice using the NOR test (Fig. 2A). The NOR test as-
sumes that a mouse not recognizing the new object
have a random chance of exploring each object
(50%). If a mouse explores more the novel object, the
recognition index will be higher than 50%. All groups
of NonTg mice exhibited a recognition index signif-
icantly different from 50%, indicating that they did
recognize the new object, independently of the diet.
Results showed that 3xTg-AD mice fed a CD or HFD
had a recognition index that did not differ from the
threshold of 50%, confirming memory impairments.
Whereas BH4 administration had no effect on NOR
in NonTg mice, the recognition index was higher in
3xTg-AD mice treated with BH4, independently of
the diet, indicating that BH4 rescued memory deficits
in these mice (Fig. 2B). Diet and BH4 treatment
did not affect the exploration time during the testing
phase. However, 3xTg-AD mice exhibited a slightly
higher total exploration time (44 ± 2 s) compared to
NonTg mice (35 ± 2 s) (Genotype effect, p = 0.0358).
Memory deficits in 3xTg-AD mice were also illus-
trated by the time of exploration of the novel object
during the testing phase, which did not differ from
the time of exploration of the familiar object, in mice
under CD and HFD diet, except for the mice treated
by BH4 (p < 0.001) (Fig. 2C). Comparison of the two
acquisition and testing phases showed that the explo-
ration ratio was significantly higher in BH4-treated
mice than in non-treated mice, only in the group fed
the CD (p < 0.05) (Fig. 2D). BH4-treated animals
were also compared directly to their respective un-
treated controls, confirming that the administration
of BH4 increased the NOR index of 3xTg-AD mice
compared to untreated controls, independently of
the diet (p < 0.01). Multivariate analyses showed no
effect of sex on the NOR index (p > 0.5).
Spontaneous locomotion in the open-field assessed
by the total distance travelled was significantly higher
in 3xTg-AD compared to NonTg mice, without a
BH4 treatment effect (Genotype effect, p < 0.001 and
diet effect, p < 0.05). However, speed was not sta-
tistically different between genotypes (NonTg mice:
11.7 ± 0.4 cm/min; 3xTg-AD: 13.2 ± 0.2 cm/min),
independently of diet or treatment (Fig. 2E).
BH4 administration had no effect on
hippocampal tau and amyloid pathologies
Since the 3xTg-AD mouse model displays an acc-
retion of both tau and A in the brain [41], we inves-
tigated whether the improvement in memory deficit
we observed after BH4 administration was linked
to changes in these two main AD neuropathologi-
cal hallmarks. First, we quantified total tau protein,
using an antibody specific for the C-terminal of both
the murine endogenous form and the human trans-
genic form, in both cytosolic and insoluble fractions.
As tau hyperphosphorylation is a key marker of
AD, we also quantified tau phosphorylated levels
at Ser369/Ser404 (PHF1), Thr231 (AT180), Thr181
(AT270), Ser202/Thr205 (AT8), and Ser202 (CP13)
in soluble and insoluble fractions in the hippocam-
pus As expected, 3xTg-AD mice displayed greater
levels of total and phosphorylated tau in the solu-
ble and insoluble fractions than NonTg mice (Fig. 3)









Animal weights and levels of monoamines and main metabolites in the striatum of NonTg and 3xTg-AD mice
Genotype Non Tg 3xTg-AD Multivariate analyses
Diet CD HFD CD HFD
Treatment Ctls BH4 Ctls BH4 Ctls BH4 Ctls BH4
N 11 12 12 14 17 15 13 15
Weight (g)(a) 37.8 ± 2.0 38.8 ± 2.5 45.5 ± 2.6 45.1 ± 2.9 35.0 ± 1.6 34.9 ± 2.0 41.0 ± 1.7 39.5 ± 2.0 Higher in males, p < 0.001
Higher after HFD, p < 0.001
Lower in 3xTg-AD, p < 0.01
Weight  (g) (b) –2.5 ± 0.6 –1.7 ± 0.4 –4.2 ± 0.5 –5.9 ± 0.7 –1.4 ± 0.4 –1.5 ± 0.7 –3.1 ± 0.6 –2.4 ± 0.7 More in HFD, p < 0.001
Less in 3xTg-AD, p < 0.01
N 11 12 10 10 16 14 13 13
DA 21.85 ± 2.12 17.19 ± 1.69 19.75 ± 1.49 22.38 ± 2.33 21.79 ± 1.36 20.91 ± 1.75 24.66 ± 3.35 24.59 ± 1.37 n.s
HVA 2.94 ± 0.30 2.66 ± 0.23 2.81 ± 0.31 3.56 ± 0.33 3.28 ± 0.18 3.37 ± 0.29 3.62 ± 0.38 3.61 ± 0.24 Higher in 3xTg-AD, p < 0.05
DOPAC 1.48 ± 0.13 1.70 ± 0.13 1.67 ± 0.13 1.98 ± 0.19 1.82 ± 0.11 1.78 ± 0.13 2.03 ± 0.26 2.04 ± 0.11 Higher in HFD, p < 0.05
5-HT 1.89 ± 0.09 1.85 ± 0.14 2.19 ± 0.14 2.01 ± 0.16 2.08 ± 0.13 2.01 ± 0.08 2.09 ± 0.14 2.08 ± 0.18 n.s
5-HIAA 1.55 ± 0.13 1.53 ± 0.12 1.82 ± 0.16 2.11 ± 0.14† 1.72 ± 0.14 1.47 ± 0.11 1.77 ± 0.17 1.54 ± 0.13 Higher in HFD, p < 0.05
5-HIAA/5-HT 0.82 ± 0.06 0.84 ± 0.06 0.82 ± 0.04 1.06 ± 0.06† 0.83 ± 0.04 0.73 ± 0.03 0.84 ± 0.05 0.75 ± 0.03 Genotype × Treatment, p < 0.001
Higher in 3xTg-AD, p < 0.01
Higher in HFD, p < 0.05
[DOPAC + 0.21 ± 0.01 0.25 ± 0.01 0.23 ± 0.01 0.26 ± 0.1 0.24 ± 0.01 0.25 ± 0.01 0.24 ± 0.01 0.23 ± 0.01 Higher with BH4, p < 0.01
HVA]/DA Genotype x Treatment, p < 0.05
Dopamine (DA), serotonin (5-HT), and their metabolites, 3,4-Dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindolacetic acid (5-HIAA) respectively, were
measured by HPLC-electrochemistry in striatum. Values are expressed as mean ± SEM (ng/mg tissue). CD, control diet; HFD, high-fat diet; Ctls, control vehicle-treated mice; BH4, BH4-treated
mice. a) Measured at sacrifice. b) Weight loss during the 10-day treatment, expressed as mean ± SEM (g). †p < 0.05 versus all other groups (Kruskal Wallis followed by nonparametric Comparisons
for each pair using Wilcoxon method).
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Fig. 2. BH4 administration improves recognition memory function in 3xTg-AD mice without affecting spontaneous locomotion. A) Recog-
nition memory was evaluated using the novel object recognition (NOR) test. B) Recognition index: (time exploring the novel (N) object/total
time exploring both N and familiar (F) objects during the testing phase)∗100. C) Total exploration time of the N and the F objects during
the testing phase. D) Ratio of total exploration time during the testing phase/acquisition phase. E) Spontaneous locomotion monitored for
1 h in an open-field (total distance travelled in cm). Values are represented as mean ± SEM with N = 7–17/group. Statistical analyses: (B)
++p < 0.01; +++p < 0.001 compared to random selection of an object (one sample t-test versus 50%); ##p = 0.0013 (Effect of BH4 Treatment,
two-way ANOVA within 3xTg-AD mice); (C) &p < 0.05, &&p < 0.01, &&&p < 0.001 between N and F objects (Wilcoxon matched paired
rank test); (D) &p < 0.05 (Wilcoxon matched paired rank test); (E) ∗∗p < 0.01 Genotype effect, (Multimodal ANOVA).
phosphorylation status of each epitope assessed were
higher in 3xTg-AD (p < 0.01 or p < 0.001) (Fig. 3A).
Similarly, total insoluble tau and its phosphorylation
status (PHF1 and CP13) were higher in 3xTg-AD
compared to NonTg mice (Fig. 3B) (Genotype effect,
p < 0.05, except p = 0.056 for CP13). BH4 admin-
istration and diet had no significant impact on the
level of tau in 3xTg-AD mice, except for the levels
of Ser202/Thr205 (AT8) phosphorylation signifi-
cantly decreased by BH4 in NonTg animals (p < 0.05)
(Fig. 3A). Western blots are shown in Supplementary
Figure 1.
We next measured soluble and insoluble A40 and
A42 levels in the parieto-temporal cortex of 3xTg-
AD mice (Fig. 4). As previously described [55], we
observed that females exhibited higher levels of A40
(Fig. 4A, B) and A42 (Fig. 4C, D) peptides than
males (Sex effect, p < 0.001). HFD exposure sig-
nificantly increased the levels of soluble A40 in
3xTg-AD mice (p = 0.02). However, BH4 adminis-
tration did not change levels of soluble or insoluble
A40 and A42 peptides, nor insoluble/soluble ratios
in the cortex of 3xTg-AD males and females (data
not shown, see Supplementary Table 3 for statistical
comparisons).
BH4 administration improves glucose tolerance
in 3xTg-AD mice
We previously evidenced glucose intolerance in the
3xTg-AD mouse model, exacerbated by HFD [55].
To assess whether the beneficial effect of BH4 admin-
istration on memory could be associated to peripheral
metabolic improvement, we performed glucose tol-
erance tests (Fig. 5). In NonTg mice, HFD and BH4
administration had no effect on the evolution of
glycemia after glucose injection (Fig. 5A) nor on the
AUC (Fig. 5B). However, results showed an HFD-
induced failure in response to glucose injection in
the 3xTg-AD mice (p < 0.001 RM ANOVA), which
was totally restored 45 min after glucose injection in
the group treated with BH4 (p < 0.05, RM ANOVA)
(Fig. 5C, D).
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Fig. 3. BH4 administration does not affect tau pathology. Hippocampal soluble (A) and insoluble (B) tau phosphorylation evaluated by
western immunoblotting, confirming higher levels in 3xTg-AD compared to NonTg mice. Values are expressed as mean ± SEM with
N = 10–15/group. Statistical analyses: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, Genotype effect (Multimodal ANOVA).
BH4 administration modulates cortical IL-1β
cytokine expression according to the diet
Given the importance of neuroinflammation in
AD etiopathology [5] and because BH4 was shown
to exhibit anti-inflammatory properties [76], we
next investigated the gene expression of major
pro-inflammatory cytokines in the parieto-temporal
cortex of mice (Fig. 6). Results showed a signifi-
cant reduced expression of IL-6 (Genotype effect,
p < 0.05) and TNF- (Genotype effect, p < 0.01)
mRNA in 3xTg-AD mice, compared to NonTg. The
exposition to HFD had no effect on mRNA expres-
sion of the 3 proinflammatory cytokines studied. BH4
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Fig. 4. BH4 administration does not affect A peptide levels in 3xTg-AD mice. Quantification of A40 (A, B) and A42 (C, D) peptides by
ELISA in soluble and insoluble fractions of parieto-temporal cortex from 3xTg-AD mice. Females and males are represented separately on
a logarithmic scale because of higher amyloid pathology in females. Values are expressed as mean ± SEM with N = 5–8/group. Statistical
analyses: ∗∗∗p < 0.001, Sex effect (Multimodal ANOVA); #p < 0.05, HFD effect in females (Multimodal ANOVA).
administration only induced a significant increase in
mRNA expression of IL-1 in NonTg mice fed the
HFD (Kruskal Wallis χ2 = 0.05, Wilcoxon, p = 0.02).
No significant change of others pro-inflammatory
markers such as the protein level measured by west-
ern blotting in the hippocampus of cyclooxygenase
2 (COX2), glial fibrillary acidic protein (GFAP), and
superoxide dismutase (SOD1) were noted (data not
shown).
Effects of BH4 administration on NO and
monoamines levels
BH4 is the mandatory cofactor of nitric oxide syn-
thases (NOS) for the synthesis of NO which is a key
modulator of vascularization but also involved in in-
flammatory responses. Thus, we evaluated the effect
of BH4 administration on NOSs protein levels in
hippocampus and on NO contents, representing as
the total nitrite and nitrate level in parieto-temporal
cortex (Fig. 7). Whereas neuronal NO synthase
(nNOS) protein expression (Fig. 7A) and nitrite +
nitrate levels (Fig. 7D) were equivalent in all exper-
imental groups, the multivariate ANOVA revealed a
significant Diet effect (p = 0.029) and a significant
Diet x Genotype interaction (p = 0.041) on eNOS
expression (Fig. 7B), with an increased expression
in 3xTg-AD compared to NonTg mice, under CD.
Moreover, results revealed a significant increase in
inducible NO synthase (iNOS) protein (Fig. 7C)
expression in the 3xTg-AD mice, as compared to
NonTg mice (Genotype effect, p = 0.005). No signif-
icant effect of the BH4 administration was found on
the different measures. Corresponding Western blots
are shown in Supplementary Figure 2.
BH4 is essential for monoamine synthesis, acting
as a cofactor for phenylalanine hydroxylase (PheOH),
tyrosine hydroxylase (TH), and tryptophane hydrox-
ylase (TRP-OH) [20]. Thus, we measured the total
amount of DA, 5-HT, and their main metabolites
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Fig. 5. BH4 administration improves glucose tolerance in 3xTg-AD mice. Glucose tolerance in response to the intraperitoneal administration
of glucose (i.p. 1 g/kg) in fasted NonTg (A, B) and 3xTg-AD mice (C, D). B–D) Area under the curves (AUC) from t = 0 to t = 120 min is
represented for all groups. Values shown are glycemia (mM) or AUC (mM/min), expressed as mean ± SEM with N = 11–17/group. Statistical
analyses: (C) $p < 0.05, $$p < 0.01 for each time point, significantly different between CD and HFD in Ctl mice; &p < 0.05, &&p < 0.01 for
each time point, significantly different between BH4 treated and Ctl mice under HFD; (D) ∗p < 0.05 Main BH4 Treatment effect; ∗∗∗p < 0.001
Main Diet effect (Multimodal ANOVA).
Fig. 6. Pro-inflammatory cytokines mRNA expression. Genic expression of IL1-, IL-6, and TNF- were measured by qRT-PCR in the
parieto-temporal cortex of 3xTg-AD and NonTg mice. Values are expressed as relative fold changes using the comparative threshold method.
Values are expressed as mean ± SEM with N = 7–17/group. Statistical analyses: ∗p < 0.05, ∗∗p < 0.01 Main Genotype effect (Multimodal
ANOVA); &p < 0.05 significantly different between controls and BH4-treated and HFD in NonTg HFD mice (Wilcoxon).
in the striatum of mice (Table 1). DA and 5-HT levels
were not affected by genotype, diet or BH4-admi-
nistration, whereas metabolites of DA (DOPAC) and
5-HT (5-HIAA), were significantly higher with HFD
(Diet effect, p < 0.05). In addition, levels of the
DA metabolite HVA were significantly higher in
3xTg-AD mice versus NonTg (Genotype effect, p <
0.05). Intriguingly, BH4 administration significantly
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Fig. 7. NOSs expression and total nitrites + nitrates. nNOS (A), eNOS (B), and iNOS (C) proteins content were measured by Western Blotting
in hippocampus. Total nitrites and nitrates (D) were measured in parieto-temporal cortex of 3xTg-AD and NonTg mice and expressed as
mol/mg of wet tissue. Values are expressed as mean ± SEM with N = 10–14/group. Statistical analyses: #p < 0.05 (Multimodal ANOVA,
interaction Genotype x Diet); ∗∗p < 0.01, Genotype effect (Multimodal ANOVA).
increased the turnover of 5-HT, as illustrated by the
increase in 5-HIAA levels and increased 5-HIAA/5-
HT ratio (p < 0.05), specifically in NonTg mice fed
the HFD, an effect not present in 3xTg-AD mice.
Moreover, BH4 administration also significantly
increased the [DOPAC+HVA]/DA ratio (p < 0.01),
suggesting a higher turnover of DA.
DISCUSSION
BH4 is the essential cofactor for NO and mono-
amine synthesis. Given its potential involvement in
key AD-associated defects, such as neuroinflamma-
tion, oxidative stress, and metabolic syndrome, we
investigated the effects of BH4 administration in
the 3xTg-AD mouse model of AD. We show that
BH4 treatment reversed object recognition deficits
in 3xTg-AD mice. This improvement was not acc-
ompanied with changes in the two classical neu-
ropathological markers of AD, but with an improved
glucose tolerance in HFD-fed 3xTg-AD mice.
BH4 administration leads to an improvement in
memory deficits in 3xTg-AD mice
Recognition memory is known to be affected in
patients in the earliest phase of AD [77]. The NOR
test, based on the innate behavior of mice to explore
novelty, is routinely used for the evaluation of mem-
ory deficits in AD mouse models [78] and has rep-
eatedly been shown to distinguish 3xTg-AD mice
from controls, from 12 months of age [42, 55, 69].
Here, we observed that a subchronic BH4 admin-
istration (15 mg/kg/day for 10 day) reversed the
recognition memory deficits observed in the 3xTg-
AD mouse model. This effect was present in all
3xTg-AD mice, either fed a control or HFD. NonTg
mice performed well at the test, so these conditions do
not allow exploring the potential beneficial effect of
BH4 on memory in cognitively normal mice. Impor-
tantly, despite more locomotor activity recorded in
3xTg-AD mice, contrasting with previous reports
[42, 79], locomotor behavior was not affected by
BH4 administration indicating that the effect of BH4
on NOR test was specific to a memory improvement
and not linked to a motor effect. It has been recently
shown that BH4 improves memory acquisition, con-
solidation, and hippocampal plasticity in mice. More
specifically, intra-cerebroventricular administration
of BH4 enhances hippocampal long-term poten-
tiation and glutamatergic transmission through an
increase in NO activity [80], which participates to
memory process and NOR performance [81]. Fur-
thermore, BH4 supplementation in individuals with
phenylketonuria (a genetic defect of phenylalanine
hydroxylase) improves working memory and neu-
ronal activity in the prefrontal cortex [82]. Then,
consistent with previous data, the present work pro-
vides evidence to consider BH4 as a potential treat-
ment for memory deficits observed in AD.
BH4 administration did not affect amyloid and
tau pathologies
3xTg-AD mice develop the two main hallmarks of
AD, amyloid plaques and tangles, as well as mem-
ory impairments [41, 42, 63, 79]. As previously
described, accumulation of A peptides was higher
in females although cognitive impairment was sim-
ilar between genders [42, 63, 79, 83, 84]. Although
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BH4 administration partly corrected memory deficits,
it had no impact on cerebral A burden or on total or
phosphorylated tau. However, A and tau modula-
tion is not a prerequisite to cognitive and memory
enhancement in mouse models. Indeed, numerous
studies show cognitive improvement without changes
in levels of amyloid and tau, particularly in 3xTg-AD
mice [42, 85, 86] or other AD models [87, 88]. Recip-
rocally, other studies report cognitive deterioration
independently of an aggravation of amyloid- or tau
pathologies [47, 62] and amyloid immunotherapies
often fail to ameliorate cognition despite an ame-
lioration of amyloid clearance and plaques [89]. In
addition, interpretation of the present data should be
limited to the study paradigm selected. Higher doses
or a longer duration of BH4 administration could
have exerted a more important impact on A and
tau pathologies. Similarly, using models with higher
brain levels of A deposits and tangles could also
provide greater sensitivity to detect changes in AD
markers. For example, several APP/PS1 transgenic
models display much aggressive accumulation of A
plaques than the 3xTg-AD model and could be bet-
ter suited to detect subtle change in A pathologies.
In any case, the present data confirms that cognitive
improvement can occur irrespectively of changes in
A and tau pathologies in a genetic model of cogni-
tive impairment.
Neuroinflammation status and brain monoamine
levels in 3xTg-AD mice
BH4, as a cofactor, is required for the activity of
NOSs, TH, and TRP-OH [20]. Thus, we assessed the
status of these pathways throughout brain measures
of protein expression for eNOS, iNOS, nNOS, NO,
and monoamine levels in 3xTg-AD and NonTg mice
under both diets. We also explored the effect of BH4
administration on these parameters. We showed that
eNOS and iNOS protein expression was increased in
the hippocampus of 3xTg-AD mice, whereas nNOS
expression and NO levels were unchanged, indepen-
dently of the diet. Higher expression of iNOS and
eNOS have been described in AD mouse models
and in the brains of AD patients, in particular in the
vicinity of amyloid plaques [90, 91]. The increased
nNOS levels and NO activity in AD brains have
been postulated to initially serve a neuroprotective
role as suggested by the selectively spared NOS-
positive neurons in AD. However, sustained increase
in NO may have deleterious effects, including oxida-
tive stress, protein misfolding, mitochondrial stress
and fragmentation, loss of synaptic function, and
apoptosis [90].
The hypothesis of an increase in eNOS activity as a
compensatory mechanism for NO which production
is reduced in AD condition because of decrease in
BH4 bioavailability is supported by a few studies in
mouse transgenic models of AD [90, 92]. Santhanam
et al. [34] observed a decreased BH4 level and NO
production in isolated microvessels of the Tg2576
mouse model of AD, whereas these impairments are
reversed by a ten-day BH4 treatment. BH4 has been
shown in several studies to increase cerebral blood
flow [93, 94]. In accordance with the impairment
of cerebral blood flow and endothelial NO signaling
dysfunctions previously described in 3xTg-AD mice
[90], a beneficial effect of BH4 supplementation on
brain vascularization could be involved in the mem-
ory improvement we observed in transgenic treated
mice.
Neuroinflammation has been frequently observed
to accompany AD neuropathology [5, 6, 89]. Our
results showed that 3xTg-AD mice expressed lower
TNF- and IL-6 mRNA transcripts compared to
NonTg mice. Previous studies reported an increase
in pro-inflammatory IL-5 and IL-12 cerebral protein
levels and an enhanced susceptibility to acute infec-
tion in 3xTg-AD mice [95]. Moreover, IL-1 has
been shown to be involved in A production and
aggregation in mouse models of AD [96, 97], and
genetic polymorphism of IL-1 is associated to a
higher risk of developing AD [98]. Transient pertur-
bations of pro-inflammatory cytokines expression are
also observed in 6-month-old 3xTg-AD mice but not
at 12 months [99]. The present observations are dif-
ferent from reports of increased cytokines in serum
or plasma from AD patients [89, 100]. However,
previous studies with transgenic mice modeling AD
neuropathology (APP/PS1 or 3xTg-AD), at around
the same age (13 and 14 months), showed equal or
lower levels of IL-1, IL-6, and TNF- in serum or
plasma compared to nontransgenic controls [45, 64,
101]. Altogether, these results suggest that 3xTg-AD
mice do not express a classical neuroinflammation,
with a global reduced expression of TNF- and IL-
6 but rather inflammatory dysfunctions that differ
according to the age they are observed, but indepen-
dent of the diet or BH4 administration.
Impairment of monoaminergic system in AD was
shown in humans both in vivo and postmortem.
Reductions of 5-HT or DA, along with their metabo-
lites and receptors, have been reported in AD
postmortem brain tissue [4]. In the 3xTg-AD model,
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abnormal 5-HT fiber sprouting in hippocampus has
been described [102]. Here, we did not observe a
significant difference in DA or 5-HT levels in str-
iata of 3xTg-AD mice, although higher concentra-
tions of DA metabolites HVA and DOPAC were
detected in transgenic animals. BH4 administration
induced a slight but significant increase of [DOPAC+
HVA]/DA and 5-HIAA/5-HT ratios, common ind-
exes of monoamine turnover, which could stem from
a BH4-induced activation of monoamine oxidase.
This effect of BH4 was mostly present in HFD-fed
NonTg animals, suggesting a blunting effect of
3xTg-AD transgenes. The impact of peripheral adm-
inistration of BH4 on brain DA and 5-HT contents is
the subject of contrasting data in the literature. Some
studies reported an increase in DA and 5-HT lev-
els [103–106], while other detect no changes [107]
following BH4 administration. Homma et al. [66]
observed an increase in DA and 5-HT cerebral con-
tents in hph-1 mice, a mouse model of peripheral
and central BH4 and monoamine deficiency, after a
7-day treatment with BH4 at the dose of 50 mg/kg.
Recently, we showed that acute administration of
BH4 enhanced synaptic DA release in the ventral
striatum, in association to a facilitated performance
in a motivational task [39]. BH4 was also found to
cross the blood-brain barrier with an uptake coeffi-
cient of 0.08 l.g–1.s–1 [19, 39]. The present data do
not provide clear evidence of a sustained modulation
of monoamine levels after chronic BH4 administra-
tion, beside a slight acceleration of DA and 5-HT
metabolism.
Limited effect of the HFD
HFD had no significant impact on memory perfor-
mance in 3xTg-AD mice, contrasting with previous
work [44, 45, 55, 58, 108]. This may be due to a
threshold or floor effect, as 3xTg-AD mice on the con-
trol diet are already cognitively impaired. Indeed, old
NonTg and 3xTg-AD mice already failed to identify
the new object.
Unexpectedly, the HFD did not have significant
effect on markers of AD neuropathologies (expect
on soluble A40 in females), contrasting with pre-
vious reports in 3xTg-AD mice [55]. While HFD
has been more rarely shown to affect tau levels [43,
47, 52, 53, 109, 110], many publications show an
aggravating effect of a HFD on brain A load in
3xTg-AD mice [43, 46, 55] and others AD model [52,
53, 58, 108, 111]. Here, the HFD increased soluble
A40 in females, while changes in A42 remained
non-significant. A simple explanation comes from
the high variability of both markers within groups,
precluding the detection of significant difference.
Another is the loss of statistical power due to the sep-
aration of males versus females that was necessary
before comparing A concentrations.
When the metabolic status matters
Diabetes and obesity are recognized risk factors
for AD [9, 112], and the interaction between the two
comorbidities can be investigated in animal models
using controlled diets [55]. The genetic induction of
AD-like pathology in the brain has been shown to lead
to peripheral glucose intolerance [63], aggravated by
HFD [47, 55]. Here, we confirmed the vulnerability
of 3xTg-AD mice to HFD-induced metabolic distur-
bances compared to NonTg mice, as they developed
more prominent peripheral glucose intolerance [55].
However, quite interestingly, the glucose intolerance
induced by this synergy of AD transgenes and HFD,
was completely reversed by BH4 administration. This
was not related to a reduction in calorie intake in BH4-
treated animals of either diet. This beneficial effect
of BH4 on metabolism is consistent with results from
previous clinical studies and studies in mouse models
of metabolic disturbances [36, 37, 113]. In particular,
BH4 treatment has been reported to improve glu-
cose tolerance and insulin resistance by suppressing
hepatic gluconeogenesis [36].
The present data suggest that a peripheral
metabolic regulation following BH4 administration
could be involved in memory improvement observed
in 3xTg-AD mice fed the HFD, with more limi-
ted central effects on classical AD pathology. This
would indicate that BH4 treatment may be more bene-
ficial in individuals with an impaired metabolic state,
such as the elderly or obese people, in which alter-
ation of BH4 pathway has been described [114, 115].
Thus, clinical studies with BH4 should consider the
metabolic status of volunteer patients.
Other clinical utility of BH4
The present data could be relevant to other preva-
lent diseases [19]. Obviously, the observed effect
of glucose tolerance support previous suggestion of
an application for biopterins in metabolic diseases
[36–38]. Because BH4 is strongly associated with
the neurotransmission of dopamine and serotonin,
neuropsychiatric diseases associated with alterations
in monoamine function such as schizophrenia [116,
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117] or depression [118–121] or autism [122, 123]
could benefit from a better understanding on the
impact of BH4 on behavior. In autism, some stud-
ies have shown an improvement of symptoms related
to cognition, communication, or hyperactivity [122,
124–126] (review in [123]). Additional studies in ani-
mal models and in large patient cohorts are needed
to fully understand BH4 mechanisms as well as it
potential as a treatment in CNS diseases.
CONCLUSION
Altogether, the results of the present study indicate
that the administration of BH4 for ten days attenuates
memory dysfunction in the 3xTg-AD model of AD.
The principal correlate observed was an improvement
of metabolic determinants (i.e., glucose response),
with no significant change in neuropathological end-
points. Given the positive effects of BH4 treatment
on recognition memory and recent multiple failures
of tau and amyloid- targeted drugs in clinical tri-
als, the present results suggest BH4 may represent a
novel promising multi-target treatment with a favor-
able safety profile.
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D, Barberger-Gateau P, Layé S, Fuchs D (2011) Chronic
low-grade inflammation in elderly persons is associated
with altered tryptophan and tyrosine metabolism: Role in
neuropsychiatric symptoms. Biol Psychiatry 70, 175-182.
[116] Richardson MA, Read LL, Reilly MA, Clelland JD, Clel-
land CL (2007) Analysis of plasma biopterin levels in
psychiatric disorders suggests a common BH4 deficit in
schizophrenia and schizoaffective disorder. Neurochem
Res 32, 107-113.
[117] Richardson MA, Read LL, Taylor Clelland CL, Reilly MA,
Chao HM, Guynn RW, Suckow RF, Clelland JD (2005)
Evidence for a tetrahydrobiopterin deficit in schizophre-
nia. Neuropsychobiology 52, 190-201.
[118] Blair JA, Barford PA, Morar C, Pheasant AE, Hamon
CG, Whitburn SB, Leeming RJ, Reynolds GP, Coppen
A (1984) Tetrahydrobiopterin metabolism in depression.
Lancet 2, 163.
[119] Curtius HC, Niederwieser A, Levine RA, Lovenberg W,
Woggon B, Angst J (1983) Successful treatment of depres-
sion with tetrahydrobiopterin. Lancet 1, 657-658.
[120] Pan L, McKain BW, Madan-Khetarpal S, McGuire M,
Diler RS, Perel JM, Vockley J, Brent DA (2011) GTP-
cyclohydrolase deficiency responsive to sapropterin and
5-HTP supplementation: Relief of treatment-refractory
depression and suicidal behaviour. BMJ Case Rep 2011,
bcr0320113927.
[121] Knapp S, Irwin M (1989) Plasma levels of tetrahydro-
biopterin and folate in major depression. Biol Psychiatry
26, 156-162.
[122] Danfors T, von Knorring AL, Hartvig P, Langstrom
B, Moulder R, Stromberg B, Torstenson R, Wester U,
Watanabe Y, Eeg-Olofsson O (2005) Tetrahydrobiopterin
in the treatment of children with autistic disorder: A
double-blind placebo-controlled crossover study. J Clin
Psychopharmacol 25, 485-489.
[123] Frye RE, Huffman LC, Elliott GR (2010) Tetrahydro-
biopterin as a novel therapeutic intervention for autism.
Neurotherapeutics 7, 241-249.
[124] Frye RE, DeLatorre R, Taylor HB, Slattery J, Melnyk
S, Chowdhury N, James SJ (2013) Metabolic effects of
sapropterin treatment in autism spectrum disorder: A pre-
liminary study. Transl Psychiatry 3, e237.
[125] Klaiman C, Huffman L, Masaki L, Elliott GR (2013)
Tetrahydrobiopterin as a treatment for autism spectrum
disorders: A double-blind, placebo-controlled trial. J
Child Adolesc Psychopharmacol 23, 320-328.
[126] Fernell E, Watanabe Y, Adolfsson I, Tani Y, Bergström
M, Hartvig P, Lilja A, von Knorring AL, Gillberg
C, Långström B (1997) Possible effects of tetrahydro-
biopterin treatment in six children with autism–clinical
and positron emission tomography data: A pilot study. Dev
Med Child Neurol 39, 313-318.
